1.380USD-0.72%Mkt Cap: 142.42M $P/E: —2d ago
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrume…
Industry Peers
Medical DevicesKey Statistics
Company
Market Cap142.42M $
Enterprise Value53.99M $
Revenue (TTM)31.05M $
Gross Profit26.80M $
Net Income (TTM)-44.63M $
Revenue/Share0.2910 USD
Last Price1.380 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees91
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.80
PEG—
EV/EBITDA-1.78
EV/Revenue1.74
P/S4.59
P/B0.92
EPS (TTM)-0.34
EPS (Forward)-0.24
52W Range
0.643060% of range1.865
52W High1.865 USD
52W Low0.6430 USD
Profitability
Gross Margin81.16%
Oper. Margin-140.72%
EBITDA Margin-97.54%
Profit Margin-135.14%
ROE-26.02%
ROA-22.04%
Growth
Revenue Growth-14.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-34.41M $
CapEx (TTM)1.77M $
FCF Margin-42.31%
FCF Yield-9.22%
Net Debt-88.44M $
Net Debt/EBITDA2.92
Balance Sheet
Debt/Equity0.10
Current Ratio12.26
Quick Ratio11.08
Book Value/Sh1.496 USD
Cash/Share1.024 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.107 USD
Upside (mean)+197.6%
Target Range2.430 USD – 5.000 USD
$2.430+197.6% to mean$5.000
# Analysts4
Ownership
Shares Out.103.21M
Float93.72M
Insiders1.65%
Institutions62.05%
Short Interest
Short Ratio1.3d
Short % Float1.17%
Short % Out.1.16%
Shares Short1.24M
Short (prev mo.)1.52M
Technical
SMA 501.210 (+14.1%)
SMA 2001.137 (+21.3%)
Beta1.49
S&P 52W Chg18.16%
Avg Vol (30d)1.00M
Avg Vol (10d)1.16M
Technical Indicators
RSI (14)64.1
MACD0.0504
MACD Signal0.0199
MACD Hist.+0.0305
BB Upper1.436 USD
BB Middle1.172 USD
BB Lower0.9078 USD
BB Width45.08%
ATR (14)0.0988 USD
Vol Ratio (20d)0.47x